



Press Release – Product Launch

Gothenburg 20 August 2003

Big Pharma orders prove successful commercial launch for Dynaflo™

The Swedish biotech tools company Cellectricon has received orders from three of the top five pharmaceutical companies. The orders verify that major pharmaceutical companies will adopt the Dynaflo™ technology which will be launched in large scale August 2003. Earlier this spring Cellectricon received a breakthrough order from AstraZeneca for the patented Dynaflo™ technology which enables aggressive productivity increase in the drug discovery process.

"The market response to our recent product launch, Dynaflo™ technology, is gratifying and we are pleased with the successful commercial launch of the company's first product," explained Jakob Lindberg, CEO of Cellectricon. "We are extremely pleased that three of the top five pharmaceutical companies have shown such a strong interest in our technology and their orders are a proof that Dynaflo™ drug-screening technology will be adopted by others."

Cellectricon's first product, the Dynaflo™ microfluidic chip, is a ground-breaking drug screening tool that can be used by pharmaceutical companies to perform drug discovery with high speed and accuracy. The Dynaflo™ microfluidic chip is based on a revolutionary microfluidic concept offering higher-throughput screening for drugs targeting ion channels, which are instrumental for brain and heart disease therapy. The Dynaflo™ technology offers dramatic productivity increase where several hundred compounds acting on ligand- and voltage-gated ion channels can be screened in one working day, compared to the current situation of an average of ten screenings per day. This higher throughput, by a factor of 10-100x with better than patch clamp data quality, facilitates the drug discovery process.

About Cellectricon

Cellectricon is a Swedish biotechnology tools company that develops microfabricated cell-based tools for the pharmaceutical and biotechnology industries. Cellectricon works at the interface between microtechnology and biology inventing products that will allow productivity increases primarily in the drug discovery process. The company was formed 2000 based on an extensive and solid patent portfolio within different areas such as high-throughput electrophysiology, patch-clamp, microfluidics, microfabrication, and electroporation. The company has been expanding steadily and rapidly from the start, growing from 2 to 28 employees today. Cellectricon is currently owned by Investor Growth Capital, Innovationskapital, and Karolinska Investment Fund together with employees and seed investors.

Download press kit and high-resolution images at: www.cellectricon.com

Contact Details:

Jakob Lindberg, CEO

Phone: + 46 - 70 - 569 5471

jakob.lindberg@cellectricon.se

Susanne Orwar, Communications Manager

Phone: +46 – 31 – 760 35 15

susanne.orwar@cellectricon.se